Research Article

TMEM100 Regulates Neuropathic Pain by Reducing the Expression of Inflammatory Factors

Table 2

Primary antibodies and IgG controls used in this study.

HostSupplier/catalog numberDilution

TMEM100Rabbit polyclonalMillipore/ABN17211 : 100(IHC), 1 : 500(Wb)
TMEM100Mouse monoclonalOrigene/TA5005321 : 100(IHC), 1 : 500(Wb)
GFAPMouse monoclonalElabscience/E-AB-220221 : 200(IHC), 1 : 1000(Wb)
Iba1Rabbit polyclonalAbcam/ab1788461 : 100(IHC), 1 : 1000(Wb)
IL-1βRabbit polyclonalAffinity/AF51031 : 1000(Wb)
IL-6Rabbit polyclonalAffinity/DF60871 : 1000(Wb)
TNF-αRabbit polyclonalAbcam/ab2151881 : 1000(Wb)
β-actinRabbit polyclonalElabscience/E-AB-200581 : 1000(Wb)
TubulinRabbit polyclonalElabscience/E-AB-200701 : 200(IHC)
IgG controlMouseElabscience/E-AB-10011 : 2000(Wb)
IgG controlRabbitElabscience/E-AB-10031 : 5000(Wb)
IgG controlMouseElabscience/E-AB-10151 : 100(IHC)
IgG controlRabbitElabscience/E-AB-10141 : 100(IHC)

TMEM100, transmembraneprotein100; GFAP, glial fibrillary acidic protein; Iba1, ionized calcium binding adaptor molecule 1; IL-1β, interleukin-1β; IL-6, interleukin-6; TNF-α, tumor necrosis factor α; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; Tubulin, β-tubulin; IgG, immunoglobulin G.